STAG2
STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Sarcomas, Renal cell carcinoma and 5 more.
Overview
Component of cohesin complex, a complex required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate.
CIViC holds 6 clinical evidence items and 0 assertions across 3 variants, naming Vemurafenib. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.00, somatic mutation 0.97). IntOGen calls it a driver in 19 cohorts (0 activating, 19 loss-of-function), covering Acute Myeloid Leukaemia, Bladder Urothelial Carcinoma, Renal Clear Cell Carcinoma, Ewing Sarcoma, Glioblastoma Multiforme, Lung Squamous Cell Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Sarcomas, Renal cell carcinoma and 5 more.
- 1 · What it is
STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Sarcomas, Renal cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
Component of cohesin complex, a complex required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped.
- 3 · How drugs use it
No product in this corpus aims at STAG2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:11355 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8N3U4 (protein name, function text, keywords and locations (REST API)); CIViC gene STAG2 (6 evidence items, 0 assertions, 3 variants; diseases: Acute Myeloid Leukaemia, Melanoma, Bladder Carcinoma, Ewing Sarcoma Of Bone, Bladder Urothelial Papillary Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000101972 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: urinary bladder cancer 0.66, endometrial cancer 0.52, sarcoma 0.62, skin cancer 0.51, myeloproliferative neoplasm 0.53, Ewing sarcoma 0.52 (GraphQL API, CC0)); IntOGen STAG2 (driver in 19 cohorts (Act 0, LoF 19); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Component of cohesin complex, a complex required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The cohesin complex may also play a role in spindle pole assembly during mitosis. Location: Nucleus; Chromosome; Chromosome, centromere (UniProt). Locus Xq25 (HGNC).
- Bladder & urothelial cancer: Open Targets association 0.66 with urinary bladder cancer (MONDO_0001187); CIViC evidence names this disease
- Sarcomas: Open Targets association 0.62 with sarcoma (MONDO_0005089)
- Renal cell carcinoma: IntOGen driver in 2 cohorts (CCRCC, PRCC)
- Endometrial cancer: Open Targets association 0.52 with endometrial cancer (MONDO_0011962); IntOGen driver in 1 cohort (UCEC)
- Thyroid cancer: IntOGen driver in 1 cohort (WDTC)
- Breast cancer: Open Targets association 0.55 with breast cancer (MONDO_0007254)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it a loss-of-function (LoF) driver in 19 cohorts; CIViC holds 6 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Ewing Sarcoma Of Bone; Bladder Urothelial Papillary Carcinoma.
Latest papers
topQuery for this target: (TITLE:"STAG2" OR ABSTRACT:"STAG2" OR TITLE:"STAG2 cohesin complex component" OR ABSTRACT:"STAG2 cohesin complex component" OR TITLE:"Cohesin subunit SA-2" OR ABSTRACT:"Cohesin subunit SA-2" OR TITLE:"SA-2" OR ABSTRACT:"SA-2" OR TITLE:"SCC3B" OR ABSTRACT:"SCC3B" OR TITLE:"SA2" OR ABSTRACT:"SA2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STAG2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetETV6
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Sarcomas (soft tissue, bone, GIST), Bladder & urothelial cancer.
- TargetASXL1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Renal cell carcinoma, Bladder & urothelial cancer.
- TargetSH2B3
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Endometrial cancer, Sarcomas (soft tissue, bone, GIST).
- TargetKMT2C
Shares Leukaemia (all types), Renal cell carcinoma, Bladder & urothelial cancer, Breast cancer (all types).
- TargetPIK3R1
Shares Leukaemia (all types), Endometrial cancer, Sarcomas (soft tissue, bone, GIST), Breast cancer (all types).
- TargetCSF2RB
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Sarcomas (soft tissue, bone, GIST), CIViC.
- TargetSF3B1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetCUX1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Thyroid cancer, Leukaemia (all types), Breast cancer (all types).